Item 7.01 Regulation FD Disclosure.

Effective January 19, 2021, executive management and certain members of the Board of Directors of Scopus BioPharma Inc. (the "Company") have begun using the materials included in Exhibit 99.1 to this report (the "Investor Presentation") in connection with presentations to existing shareholders of the Company, potential investors of the Company, and the investment community. The Investor Presentation is incorporated into this Item 7.01 by reference.

Without limiting the generality of the foregoing, the "Disclaimers" disclosure contained in the Investor Presentation is incorporated by reference into this Item 7.01. The information contained in this Item 7.01 shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and such information is not incorporated by reference into any registration statements or other document filed under the Securities Act of 1933, as amended or the Exchange Act, regardless of the general incorporation language contained in such filing, except as shall be expressly set forth by specific reference to this filing.




Item 8.01 Other Events.

On January 19, 2021, the Company issued a press release announcing the completion of clinical lot manufacturing fulfilling the requirements for the planned Phase 1 clinical trial for non-Hodgkin's lymphoma. A copy of this press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.




Exhibit Number   Description
  99.1             Investor Presentation (January 2021)
  99.2             Press Release dated January 19, 2021

© Edgar Online, source Glimpses